Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Glomerulonephritis Market Size, Value And Growth Trends Through 2030

The market for glomerulonephritis treatments has experienced consistent expansion, projected to increase from $11.61 billion in 2025 to $12.18 billion in 2026, reflecting a compound annual growth rate of 5.0%. Factors contributing to this upward trend in the past include the rising incidence of autoimmune conditions, increased utilization of kidney biopsies for diagnosis, the proliferation of specialized nephrology clinics, the availability of medications that suppress the immune system, and the broader reach of diagnostic laboratory services.

The market for glomerulonephritis is poised for consistent expansion over the upcoming years, projected to reach $14.66 billion by 2030, experiencing a compound annual growth rate of 4.7%. This anticipated increase stems from enhancements in diagnostic capabilities for kidney conditions, the progression of individualized nephrology approaches, a rise in the incidence of chronic kidney disease, the broader availability of specialized kidney care, and better patient compliance with treatment regimens. Key developments anticipated during this forecast period include a heightened emphasis on identifying kidney diseases at an earlier stage, a greater utilization of therapies that suppress the immune system, wider adoption of diagnostic tests relying on biomarkers, increased availability of services supporting dialysis patients, and more effective management of long-term health conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

Glomerulonephritis Market Industry Drivers: What Is Driving Revenue Growth?

The increasing incidence of kidney ailments is anticipated to fuel the expansion of the glomerulonephritis market in the future. Kidney ailments encompass a spectrum of conditions impacting the kidneys’ structure or function, resulting in compromised filtration capabilities, reduced waste expulsion, and an imbalance in bodily fluids. This escalating rate of kidney ailments can be attributed to demographic shifts like an aging global population, the growing prevalence of chronic health issues such as diabetes and high blood pressure, and prevalent lifestyle choices. These kidney ailments can instigate glomerulonephritis through mechanisms involving immune system dysregulation, persistent inflammation, or physical damage, ultimately impairing the kidneys’ filtration efficiency and overall performance. For illustration, as reported by Kidney Research UK in June 2023, an estimated 7.19 million individuals in the United Kingdom were grappling with chronic kidney disease in 2023, a figure that constitutes over 10% of the UK populace and is forecast to climb to 7.61 million individuals by 2033. Consequently, the burgeoning number of individuals suffering from kidney disorders is set to be a key driver for the growth within the glomerulonephritis market.

Glomerulonephritis Market Segment Analysis: What Are The Major Market Categories?

The glomerulonephritis market covered in this report is segmented –

1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

#Glomerulonephritis Market Growth Trends: What Is Influencing The Future Outlook?

Key players within the glomerulonephritis sector are prioritizing the creation of cutting-edge therapies that avoid immune suppression, aiming to satisfy existing gaps in care and enhance patient results. Such non-immunosuppressive therapies are designed to manage ailments without detrimentally impacting the body’s defense mechanisms. A significant development occurred in September 2024 when Travere Therapeutics Inc., a pharmaceutical firm based in the United States, brought FILSPARI (sparsentan) to market, having received approval from the Food and Drug Administration (FDA) for the treatment of IgA nephropathy, a specific kidney disorder. This medication stands out as the sole non-immunosuppressive option demonstrated to markedly reduce the deterioration of kidney function in individuals affected by this condition. The authorization of FILSPARI represents a pivotal advance in managing IgA nephropathy, recognized as the most prevalent form of primary glomerulonephritis, thereby introducing a novel therapeutic avenue for patients who previously faced restricted treatment possibilities. This regulatory milestone underscores Travere’s dedication to bettering the lives of those afflicted with kidney ailments.

Glomerulonephritis Market Leading Companies Driving Competitive Growth

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., Chinook Therapeutics, Purespring Therapeutics, Walden Biosciences, Visterra Inc.

Access The Complete Glomerulonephritis Market Report:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

Glomerulonephritis Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the glomerulonephritis market in 2025. The regions covered in the glomerulonephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model